Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NORLUTATE.
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium. Ethinyl estradiol is an estrogen that provides cycle control and contributes to contraceptive efficacy. Ferrous fumarate provides iron supplementation.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol, and 75 mg ferrous fumarate) orally once daily for 28 days, without interruption. Take the first tablet on the first day of menstrual bleeding.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Norethindrone: 8-11 hours (terminal). Ethinyl estradiol: 10-20 hours (terminal). Clinical context: Steady-state achieved after 5-7 days; half-life supports once-daily dosing.
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Norethindrone acetate and ethinyl estradiol are primarily excreted in urine (40-60% as metabolites) and feces (20-40% as metabolites). Ferrous fumarate is absorbed and iron is utilized; unabsorbed iron is excreted in feces.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin